[1] 申民强, 孙趁意, 刘占举.B7-H1及其受体PD-1分子在原发性肝癌组织中的表达及临床意义[J].世界华人消化杂志, 2008, 16(27):3110-3113.
[2] ZHAO Q Y, HUANG Z L, HE MH, et al.BTLA identifies dysfunctional PD-1-expressing CD4+T cells in human hepatocellular carcinoma[J].Oncoimmunology, 2016, 5(12):e1254855.
[3] KA K, RAZA M, TIWARI B K.Interferon-gamma (IFN-γ):exploring its implications in infectious diseases[J].Biomol Concepts, 2018, 9(1):64-79.
[4] JENKINS R W, BARBIE D A, FLAHERTY K T, et al.Mechanisms of resistance to immune checkpoint inhibitors[J].Br J Cancer, 2018, 118(1):9-16.
[5] 中华医学会肝病学分会, 感染病学分会.慢性乙型肝炎防治指南[J].中华肝脏病杂志, 2011, 19(1):13-24.
[6] 中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9(6):324.
[7] 胡金伟, 张峰波, 张丽, 等.自身免疫性肝炎部分患者外周血Th17细胞/调节性T细胞比值及其相关细胞因子增加[J].细胞与分子免疫性杂志, 2016, 32(9):1248-1250.
[8] HAN Y Y, LIU D, LI L H.PD-1/PD-L1 pathway:current researches in cancer[J].Am J Cancer Res, 2020, 10(3):727-742.
[9] 赵婷婷, 张清媛.PD-1/PD-L1介导的肿瘤免疫逃逸在肿瘤微环境中的研究进展[J].现代肿瘤医学, 2021, 29(3):520-521.
[10] LANGHANS B, NISCHALKE H D, KRAMER B, et al.Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma[J].Cancer Immunol Immunother, 2019, 68(12):2055-2066.
[11] MA L J, FENG F L, DONG L Q.Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma[J].Theranostics, 2018, 8(20):5690-5702.
[12] 庞盼, 朱玥洁, 贾斌, 等.布鲁菌病患者血清中可溶性程序性死亡蛋白1及其配体的水平升高[J].细胞与分子免疫学杂志, 2016, 32(12):1675-1678.
[13] NDUOM E K, WEI J, YAGHI N K, et al.PD-L1 expression and prognostic impact in glioblastoma[J].Neuro Oncol, 2016, 18(2):195-205.
[14] 李海洋, 戴素华, 张伟, 等.胃癌患者外周血T淋巴细胞亚群、PD-1水平的变化与预后的关系分析[J].现代医学, 2018, 46(10):1119-1122.
[15] KAMADA T, TOGASHI Y, TAY, et al.PD-1+regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J].Proc Natl Acad Sci U S A, 2019, 116(20):9999-10008.
[16] KAK G, RAZA M, TIWARI B K.Interferon-gamma (IFN-γ):Exploring its implications in infectious diseases[J].Biomol Concepts, 2018, 9(1):64-79.
[17] MANDAIM, HAMANISHIJ, ABIKO K, et al.Dual faces of IFN-γ in cancer progression:a role of PD-L1 induction in the determination of pro-and antitumor immunity[J].Clin Cancer Res, 2016, 22(10):2329-2334.
[18] SETO T, SAM D, PAN M, et al.Mechanisms of primary and secondary resistance to immune checkpoint inhibitors in cancer[J].Med Sci, 2019, 7(2):14. |